Announcements Trials
Browse Landscape

Phase

Phase 1 11Phase 2 5Phase 2/3 2Phase NA 1Phase EARLY_PHASE1 1Phase 3 1Phase 1/2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 15Neoplasm Metastasis 13Squamous Cell Carcinoma of Head and Neck 11Neoplasms 11Prostatic Neoplasms 10Breast Neoplasms 9Recurrence 7Ovarian Neoplasms 7Myasthenia Gravis 7Lung Neoplasms 7Leukemia, Myeloid, Acute 7Stomach Neoplasms 6Head and Neck Neoplasms 6Colorectal Neoplasms 6Lymphoma, Large B-Cell, Diffuse 5Fatigue 5Pancreatic Neoplasms 4Oropharyngeal Neoplasms 4Melanoma 4Fallopian Tube Neoplasms 4Colonic Neoplasms 4Urinary Bladder Neoplasms 3Rectal Neoplasms 3Peritoneal Neoplasms 3Mouth Neoplasms 3Glioblastoma 3Cholangiocarcinoma 3Carcinoma, Hepatocellular 3Anorexia 3Adenocarcinoma Of Esophagus 3

Interventions

Temozolomide 2veliparib 1Radiotherapy 1Radiation 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Contrast Media 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Gliosarcoma × 90 days × Clear all
NCT02152982 2026-04-28

Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
447 enrolled 20 charts
CNSSarcoma

Glioblastoma, Gliosarcoma

NCT04396860 2026-04-22

Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

National Cancer Institute (NCI)

Phase 2/3 Completed
159 enrolled 17 charts
Sarcoma

Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡